Baird Radford - May 15, 2025 Form 4 Insider Report for Allakos Inc. (ALLK)

Role
Chief Financial Officer
Signature
/s/ H. Baird Radford
Stock symbol
ALLK
Transactions as of
May 15, 2025
Transactions value $
$0
Form type
4
Date filed
5/15/2025, 04:05 PM
Previous filing
Mar 7, 2025
Next filing
Sep 5, 2025
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Radford Harlan Baird Chief Financial Officer 149 COMMONWEALTH DR, SUITE 1090, MENLO PARK /s/ H. Baird Radford 2025-05-15 0001398311

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ALLK Common Stock Disposed to Issuer -163K -100% 0 May 15, 2025 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -27.6K -100% $0.00 0 May 15, 2025 Common Stock 27.6K $105.16 Direct F3
transaction ALLK Stock Option (right to buy) Disposed to Issuer $0 -194K -100% $0.00 0 May 15, 2025 Common Stock 194K $7.20 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Baird Radford is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may continue.

Explanation of Responses:

Id Content
F1 Includes 128,339 shares represented by restricted stock units ("RSUs"). Each RSU represents the Reporting Person's right to receive one share of Common Stock of the Issuer.
F2 Disposed of pursuant to the terms of that certain Agreement and Plan of Merger, dated April 1, 2025, by and among the Issuer, Concentra Biosciences, LLC and Concentra Merger Sub III, Inc. (the "Merger Agreement") in exchange for $0.33 in cash per share.
F3 This option was cancelled without consideration pursuant to the terms of the Merger Agreement.